Choosing treatment options for patients with relapsed/refractory multiple myeloma

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl. J. Med. 351(18), 1860–1873 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson KC, Kyle RA, Rajkumar SV et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 22(2), 231–239 (2008).
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Avet-Loiseau H, Gouraud W et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27(2), 473–481 (2013).
   PubMed Web of Science ®Google Scholar
• Moreau P, Minvielle S. Multiple myeloma: so much progress, but so many unsolved questions Haematologica 98(4), 487–489 (2013).
   PubMedGoogle Scholar
• Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur. J. Haematol. 86, 1–15 (2011).
   Google Scholar
• Moreau P. The future of therapy for relapsed/refractory Multiple Myeloma: emerging agents and novel treatment strategies. Sem. Hematol. 49(3), S33–S46 (2012).
   Google Scholar
• Castelli R, Cannavò A, Conforti F et al. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacol. Immunotoxicol. 34, 740–753 (2012).
   PubMed Web of Science ®Google Scholar
• Moehler T, Goldschmidt H. Therapy of relapsed and refractory multiple myeloma: recent results. Cancer Res. 183, 239–271 (2011).
   Google Scholar
• Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N. Engl. J. Med. 335, 91–97 (1996).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Dimopoulos MA, Wang M et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95, 1738–1744 (2010).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Christoulas D et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24, 1769–1778 (2010).
   PubMed Web of Science ®Google Scholar
• Lonial S. Relapsed MM. Hematology Am. Soc. Hematol. Educ. Program 303–309 (2010).
   PubMedGoogle Scholar
• Lokhorst H, Einsele H, Vesole D et al. International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J. Clin. Oncol. 28(29), 4521–4530 (2010).
   PubMed Web of Science ®Google Scholar
• Bladé J, Rosiñol L, Cibeira MT et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 115(18) 3655–3663 (2010).
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Mikhael J, Winter A et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol. Blood Marrow Transplant. 18(5), 773–779 (2012).
   Google Scholar
• Olin RL, Vogl DT, Porter DL et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 43, 417–422 (2009).
   PubMed Web of Science ®Google Scholar
• Michaelis LC, Saad A, Zhong X et al. Salvage Second Hematopoietic Cell Transplantation in Myeloma. Biol. Blood Marrow Transplant. 19, 760–766 (2013).
   Google Scholar
• Morris C, Iacobelli S, Brand R et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J. Clin. Oncol. 22, 1674–1678 (2004).
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24, 22–32 (2010).
   PubMed Web of Science ®Google Scholar
• Kneller A, Raanani P, Avigdor A et al. Therapy with thalidomide in refractory multiple myeloma patients – the revival of an old drug. Br. J. Haematol. 108, 391–393 (2000).
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• Mohty M, Attal M, Marit G et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 35, 165–169 (2005).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Zomas A et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol. J. 5, 112–117 (2004).
   PubMedGoogle Scholar
• García-Sanz R, González-Porras JR, Hernández JM et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18, 856–8 (2004).
   PubMed Web of Science ®Google Scholar
• Kropff M, Baylon HG, Hillengass J et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica 97, 784–791 (2012).
   PubMed Web of Science ®Google Scholar
• Kastris E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin. Pharmacother. 8, 497–509 (2007).
   PubMedGoogle Scholar
• Richardson PG, Mitsiades C, Hideshima T et al. Lenalidomide in multiple myeloma. Expert Rev. Anticancer Ther. 6, 1165–1173 (2006).
   PubMed Web of Science ®Google Scholar
• Castelli R, Cassin R, Cannavò A et al. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin. Lymphoma Myeloma Leuk. 13, 1–7 (2013).
   PubMed Web of Science ®Google Scholar
• Revicki DA, Brandenburg NA, Muus P et al. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial. Leuk. Res. 37(3), 259–265 (2013).
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Delfau-Larue MH, Delfau-Larue MH et al. Lenalidomide in diffuse large B-cell lymphoma. Adv. Hematol. 2012, 5 (2012).
   Google Scholar
• Eve HE, Carey S, Heise CC et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br. J. Haematol. 159, 154–163 (2012).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23, 2147–2152 (2009).
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22, 3269–3276 (2004).
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br. J. Haematol. 141, 41–51 (2008).
   PubMed Web of Science ®Google Scholar
• Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin. Investig. Drugs 20, 691–700 (2011).
   Google Scholar
• Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008–5014 (2009).
   PubMed Web of Science ®Google Scholar
• Lacy M, Allred JB, Gertz MA et al. Pomalidomide plus low dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood 118, 2970–2975 (2011).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 15(110), 3557–3560 (2007).
   Google Scholar
• Haynes R, Leung N, Kyle R, Winearls CG. Myeloma kidney: improving clinical outcomes? Adv. Chronic Kidney Dis. 19(5), 342–351 (2012).
   PubMedGoogle Scholar
• Dimopoulos MA, Roussou M, Gkotzamanidou M et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27(2), 423–429 (2013).
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Mateos MV, Gutierrez NC et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121(6), 884–892 (2013).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Sonneveld P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21, 151–157 (2007).
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119(4), 940–948 (2012).
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M et al. A phase 2 study of single-agent carfilzomib (PX-171–003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(4), 2817–2825 (2012).
   PubMedGoogle Scholar
• Jagannath S, Vij R, Stewart AK et al. An open-label single-arm pilot phase II study (PX-171–003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 12, 310–318 (2012).
   PubMed Web of Science ®Google Scholar
• Wang M, Giralt S, Delasalle K et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12, 235–239 (2007).
   PubMed Web of Science ®Google Scholar
• Garderet L, Iacobelli S, Moreau P et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005–04 randomized phase iii trial from the chronic leukemia working party of the European group for blood and marrow transplantation. J. Clin. Oncol. 30(20), 2475–2482 (2012).
   PubMed Web of Science ®Google Scholar
• Morabito F, Gentile M, Mazzone C et al. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood 118, 5759–5766 (2011).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades CS, Laubach JP et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk. Res. 37(7), 829–837 (2013).
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma Eur. J. Haematol. 90(6), 441–468 (2013).
   PubMed Web of Science ®Google Scholar
• Lentzsch S, O'Sullivan A, Kennedy RC et al. Combination of bendamustine, lenalidomide, and dexamethasone (bld) in patients with refractory or relapsed multiple myeloma is safe and highly effective: results of phase i/ii open-label, dose escalation study. Blood 119(20), 4608–4613 (2012).
   PubMed Web of Science ®Google Scholar
• Rodon P, Hulin C, Pegourie B et al. Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): the Intergroupe Francophone du Myélome (IFM) 2009–01 protocol. 2012 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 30(15 Suppl.), 8014 (2012).
   Google Scholar
• Cavo M, Zamagni E, Cellini C et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100, 2272–2273 (2002).
   PubMed Web of Science ®Google Scholar
• Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J. Thromb. Haemost. 1, 421–422 (2003).
   PubMed Web of Science ®Google Scholar
• Castelli R, Ferrari B, Cortelezzi A et al. Thromboembolic complications in malignant haematological disorders. Curr. Vasc. Pharmacol. 8, 482–494 (2010).
   PubMedGoogle Scholar
• Elice F, Rodeghiero F. Hematologic malignancies and thrombosis. Thromb. Res. 129(3), 360–366 (2012).
   PubMedGoogle Scholar
• Niesvizky R, Naib T, Christos PJ et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Haematol. 138(5), 640–643 (2007).
   PubMedGoogle Scholar
• Adès L, Le Bras F, Sebert M et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica 97, 213–218 (2012).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Delforge M. Incidence of second primary malignancy (SPM) in melphalan prednisone-lenalidomide combination followed by lenalidomide maintenance (MP-R) in newly diagnosed multiple myeloma patients age 65 or older. J. Clin. Oncol. 29(Suppl.), Abstract 8007 (2011).
   PubMedGoogle Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J. Clin. Oncol. 26(29), 4784–4790 (2008).
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 12(15), 4628–35 (2006)
   PubMed Web of Science ®Google Scholar
• Iancu-Rubin C, Gajzer D, Mosoyan G et al. Panobinostat (LBH589)-induced acetylation of tubulin impairs megacaryocyte maturation and platelet formation. Exp. Hematol. 40(7), 564–574 (2012).
   PubMed Web of Science ®Google Scholar
• Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin. Hematol. 49(Suppl. 1), S16–S32 (2012).
   PubMedGoogle Scholar
• Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer 45, 647–652 (1980).
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 16, 593–602 (1998).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM et al.National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989–1999 (2010).
   PubMed Web of Science ®Google Scholar
• Mohty B, El-Cheik J, Yakoub-Agha I et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Leukemia 26, 73–85 (2012).
   PubMed Web of Science ®Google Scholar
• Larocca A, Cavallo F, Bringhen S et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(26), 933–939 (2012).
   PubMedGoogle Scholar
• Egan JB, Shi CX, Tembe W et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120(5), 1060–1066 (2012).
   PubMed Web of Science ®Google Scholar
• Keats JJ, Chesi M, Egan JB et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120(5), 1067–1076 (2012).
   PubMed Web of Science ®Google Scholar
• Cavo M, Galieni P, Tassi C et al. M-2 protocol for melphalan-resistant and relapsing multiple myeloma. Eur. J. Haematol. 40(2), 168–173 (1998).
   Google Scholar
• Forgeson GV, Selby P, Lakhani S et al. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br. J. Cancer 58(4), 469–473 (1988).
   PubMedGoogle Scholar
• Lokhorst HM, Meuwissen OJ, Bast EJ et al. VAD chemotherapy for refractory multiple myeloma. Br. J. Haematol. 71(1), 25–30 (1989).
   PubMedGoogle Scholar
• Petrucci MT, Avvisati G, Tribalto M et al. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment. Eur. J. Haematol. 42(3), 233–237 (1989).
   PubMedGoogle Scholar
• Delain M, Linassier C, Petitdidier C et al. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. J. Clin. Oncol. 12(12), 2706–2713 (1994).
   PubMedGoogle Scholar
• Fosså A, Muer M, Kasper C et al. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia 12(3), 422–426 (1998).
   PubMedGoogle Scholar
• Parameswaran R, Giles C, Boots M et al. CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br. J. Haematol. 109(3), 571–575 (2000).
   PubMedGoogle Scholar
• Lee CK, Barlogie B, Munshi N et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J. Clin. Oncol. 15(21), 2732–2739 (2000).
   Google Scholar
• Anagnostopoulos A, Weber D, Rankin K et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. 12, 768–771 (2003).
   Google Scholar
• Kyriakou C, Thomson K, D'Sa S et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br. J. Haematol. 129(6), 763–770 (2005).
   PubMed Web of Science ®Google Scholar
• Hovenga S, Daenen SMGJ, de Wolf JTM et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann. Hematol. 84, 311–316 (2005).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avonto I, Bruno B et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur. J. Haematol. 76, 273–277 (2006).
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 22 357, 2133–2142 (2007).
   Google Scholar
• Dimopoulos M, Spencer A Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 11, 357, 2123–2132 (2007).
   Google Scholar
• Knop S, Gerecke C, Liebisch P et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 30, 113, 4137–4143 (2009).
   Google Scholar
• Schey SA, Morgan GJ Ramasamy K et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiple relapsed/refractory myeloma patients; a phase I/II study. Br. J. Haematol. 150, 326–333 (2010).
   PubMed Web of Science ®Google Scholar
• Richardson P, Barlogie B Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson JR et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br. J. Haematol. 143, 537–540 (2008).
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yang HH, Sadler K et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 20(24), 937–944 (2006).
   Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 1(25), 3892–3901 (2007).
   Google Scholar
• Kropff M, Bisping G, Schuck E et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br. J. Haematol. 138(3), 330–337 (2007).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Gay F, Bringhen S et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann. Oncol. 19(6), 1160–1165 (2008).
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee H, Williams C et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br. J. Haematol. 144(6), 887–894 (2009).
   PubMedGoogle Scholar
• Vij R, Siegel DS, Jagannath S et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol. 158(6), 739–748 (2012).
   PubMed Web of Science ®Google Scholar